Thomas E Schlaepfer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7474328/publications.pdf

Version: 2024-02-01

163 papers

12,457 citations

23567 58 h-index 26613 107 g-index

214 all docs

214 docs citations

times ranked

214

10003 citing authors

#	Article	IF	Citations
1	The psychological burden of a two-stage exchange of infected total hip and knee arthroplasties. Journal of Health Psychology, 2022, 27, 470-480.	2.3	12
2	Diverging prefrontal cortex fiber connection routes to the subthalamic nucleus and the mesencephalic ventral tegmentum investigated with long range (normative) and short range (ex-vivo) Tj ETQq0	0 02r.gBT/	Overdock 10 Tf
3	Evidence and expert consensus based German guidelines for the use of repetitive transcranial magnetic stimulation in depression. World Journal of Biological Psychiatry, 2022, 23, 327-348.	2.6	4
4	"The Heart Asks Pleasure Firstâ€â€"Conceptualizing Psychiatric Diseases as MAINTENANCE Network Dysfunctions through Insights from sIMFB DBS in Depression and Obsessive–Compulsive Disorder. Brain Sciences, 2022, 12, 438.	2.3	4
5	Efficacy of superolateral medial forebrain bundle deep brain stimulation in obsessive-compulsive disorder. Brain Stimulation, 2022, 15, 582-585.	1.6	5
6	Resolving dyskinesias at sustained anti-OCD efficacy by steering of DBS away from the anteromedial STN to the mesencephalic ventral tegmentum – case report. Acta Neurochirurgica, 2022, 164, 2303-2307.	1.7	4
7	Deep brain stimulation for obsessive–compulsive disorder: a crisis of access. Nature Medicine, 2022, 28, 1529-1532.	30.7	36
8	Deep brain stimulation for refractory obsessive-compulsive disorder (OCD): emerging or established therapy?. Molecular Psychiatry, 2021, 26, 60-65.	7.9	54
9	Neuromodulation in Psychiatric disorders: Experimental and Clinical evidence for reward and motivation network Deep Brain Stimulation: Focus on the medial forebrain bundle. European Journal of Neuroscience, 2021, 53, 89-113.	2.6	23
10	Effects of magnetic seizure therapy on anterograde and retrograde amnesia in treatmentâ€resistant depression. Depression and Anxiety, 2020, 37, 125-133.	4.1	6
11	Deep brain stimulation for major depression: A prototype of a personalized treatment in psychiatry. , 2020, , 83-89.		O
12	Deep Brain Stimulation for Major Depression and Obsessive-Compulsive Disorder—Discontinuation of Ongoing Stimulation. Psych, 2020, 2, 174-185.	1.6	1
13	Johann Bernhard Aloys von Gudden: The Unrecognized Role of the Psychiatrist and Neuroanatomist in Modern Stereotactic Neurosurgery. Stereotactic and Functional Neurosurgery, 2020, 98, 65-69.	1.5	2
14	Tractographic description of major subcortical projection pathways passing the anterior limb of the internal capsule. Corticopetal organization of networks relevant for psychiatric disorders. NeuroImage: Clinical, 2020, 25, 102165.	2.7	52
15	Beyond antidepressant effects of deep brain stimulation – A systematic qualitative approach. Personalized Medicine in Psychiatry, 2020, 23-24, 100063.	0.1	1
16	Frontal white matter architecture predicts efficacy of deep brain stimulation in major depression. Translational Psychiatry, 2019, 9, 197.	4.8	32
17	Surgical decision making for deep brain stimulation should not be based on aggregated normative data mining. Brain Stimulation, 2019, 12, 1345-1348.	1.6	24
18	Deep brain stimulation: current challenges and future directions. Nature Reviews Neurology, 2019, 15, 148-160.	10.1	721

#	Article	IF	Citations
19	Machine learningâ€"aided personalized DTI tractographic planning for deep brain stimulation of the superolateral medial forebrain bundle using HAMLET. Acta Neurochirurgica, 2019, 161, 1559-1569.	1.7	24
20	Treatment resistance in major depression is correlated with increased plasma levels of neurofilament light protein reflecting axonal damage. Medical Hypotheses, 2019, 127, 159-161.	1.5	11
21	Superolateral medial forebrain bundle deep brain stimulation in major depression: a gateway trial. Neuropsychopharmacology, 2019, 44, 1224-1232.	5.4	109
22	Putative novel neuromodulatory treatments for affective disorders – What might emerge?. Personalized Medicine in Psychiatry, 2019, 17-18, 46-50.	0.1	1
23	Discontinuation of Superolateral Medial Forebrain Bundle Deep Brain Stimulation for Treatment-Resistant Depression Leads to Critical Relapse. Biological Psychiatry, 2019, 85, e23-e24.	1.3	14
24	Clinical Predictors of Response to Magnetic Seizure Therapy in Depression. Journal of ECT, 2019, 35, 48-52.	0.6	7
25	Deep brain stimulation of the supero-lateral branch of the medial forebrain bundle does not lead to changes in personality in patients suffering from severe depression. Psychological Medicine, 2018, 48, 2684-2692.	4.5	14
26	The anatomy of the human medial forebrain bundle: Ventral tegmental area connections to reward-associated subcortical and frontal lobe regions. NeuroImage: Clinical, 2018, 18, 770-783.	2.7	93
27	Tractography-assisted deep brain stimulation of the superolateral branch of the medial forebrain bundle (slMFB DBS) in major depression. Neurolmage: Clinical, 2018, 20, 580-593.	2.7	69
28	Being open minded about neuromodulation trials: Finding success in our "failures― Brain Stimulation, 2017, 10, 181-186.	1.6	31
29	The medial forebrain bundle as a target for deep brain stimulation for obsessive-compulsive disorder. CNS Spectrums, 2017, 22, 282-289.	1.2	81
30	Acute antidepressant effects of deep brain stimulation $\hat{a}\in$ Review and data from slMFB-stimulation. Personalized Medicine in Psychiatry, 2017, 3, 1-7.	0.1	6
31	Deep brain stimulation to the medial forebrain bundle for depression-long-term outcomes and a novel data analysis strategy. Brain Stimulation, 2017, 10, 664-671.	1.6	118
32	Deep brain stimulation for bipolar disorderâ€"review and outlook. CNS Spectrums, 2017, 22, 254-257.	1.2	27
33	Degree of Postictal Suppression Depends on Seizure Induction Time in Magnetic Seizure Therapy and Electroconvulsive Therapy. Journal of ECT, 2017, 33, 167-175.	0.6	16
34	Walking away from depression-motor activity increases ratings of mood and incentive drive in patients with major depression. Psychiatry Research, 2017, 247, 68-72.	3.3	13
35	Autonomy in Depressive Patients Undergoing DBS-Treatment: Informed Consent, Freedom of Will and DBS' Potential to Restore It. Frontiers in Integrative Neuroscience, 2017, 11, 11.	2.1	10
36	Arachnophobia alleviated by subthalamic nucleus stimulation for Parkinson's disease. Journal of Neural Transmission, 2016, 123, 631-635.	2.8	0

#	Article	IF	CITATIONS
37	Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry, 2015, 14, 64-73.	10.4	293
38	Aberrant NMDA receptor DNA methylation detected by epigenome-wide analysis of hippocampus and prefrontal cortex in major depression. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 331-341.	3.2	55
39	Deep Brain Stimulation for Major Depression—Steps on a Long and Winding Road. Biological Psychiatry, 2015, 78, 218-219.	1.3	27
40	The impact of Parkinson's disease and subthalamic deep brain stimulation on reward processing. Neuropsychologia, 2015, 75, 11-19.	1.6	26
41	Diminished appetitive startle modulation following targeted inhibition of prefrontal cortex. Scientific Reports, 2015, 5, 8954.	3.3	13
42	Effects of Electroconvulsive Therapy and Magnetic Seizure Therapy on Acute Memory Retrieval. Journal of ECT, 2015, 31, 13-19.	0.6	28
43	Oxytocin Facilitates the Extinction of Conditioned Fear in Humans. Biological Psychiatry, 2015, 78, 194-202.	1.3	210
44	Update on Neuromodulation for Treatment-Resistant Depression. F1000Research, 2015, 4, 1389.	1.6	30
45	Bilateral bispectral index monitoring during and after electroconvulsive therapy compared with magnetic seizure therapy for treatment-resistant depression. British Journal of Anaesthesia, 2014, 112, 695-702.	3.4	22
46	Neuromodulation for Treatment Resistant Depression: State of the Art and Recommendations for Clinical and Scientific Conduct. Brain Topography, 2014, 27, 12-19.	1.8	16
47	Affective Neuroscience Strategies for Understanding and Treating Depression. Clinical Psychological Science, 2014, 2, 472-494.	4.0	68
48	Brain stimulation treatments for depression. World Journal of Biological Psychiatry, 2014, 15, 167-168.	2.6	12
49	Deep Brain Stimulation of the Human Reward System for Major Depressionâ€"Rationale, Outcomes and Outlook. Neuropsychopharmacology, 2014, 39, 1303-1314.	5.4	126
50	An Oxytocin-Induced Facilitation of Neural and Emotional Responses to Social Touch Correlates Inversely with Autism Traits. Neuropsychopharmacology, 2014, 39, 2078-2085.	5.4	214
51	Psycho-Informatics: Big Data shaping modern psychometrics. Medical Hypotheses, 2014, 82, 405-411.	1.5	139
52	Consensus on guidelines for stereotactic neurosurgery for psychiatric disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1003-1008.	1.9	150
53	Comparable seizure characteristics in magnetic seizure therapy and electroconvulsive therapy for major depression. European Neuropsychopharmacology, 2013, 23, 1541-1550.	0.7	33
54	Reply to: Medial Forebrain Bundle Stimulationâ€"Speed Access to an Old or Entry into a New Depression Neurocircuit?. Biological Psychiatry, 2013, 74, e45-e46.	1.3	19

#	Article	IF	CITATIONS
55	Nicotinic Acetylcholine Receptors Contribute to Learning-induced Metaplasticity in the Hippocampus. Journal of Cognitive Neuroscience, 2013, 25, 986-997.	2.3	13
56	Rapid Effects of Deep Brain Stimulation for Treatment-Resistant Major Depression. Biological Psychiatry, 2013, 73, 1204-1212.	1.3	502
57	Not too much reason for excitement: Deep Brain Stimulation for Anorexia Nervosa. European Eating Disorders Review, 2013, 21, 509-511.	4.1	5
58	Chronic depression as a model disease for cerebral aging. Dialogues in Clinical Neuroscience, 2013, 15, 77-85.	3.7	24
59	Toward an Emergent Consensus–International Perspectives on Neuroethics of Deep Brain Stimulation for Psychiatric Disorders–A Tower of Babel?. AJOB Neuroscience, 2012, 3, 1-3.	1.1	1
60	How Happy Is Too Happy? Euphoria, Neuroethics, and Deep Brain Stimulation of the Nucleus Accumbens. AJOB Neuroscience, 2012, 3, 30-36.	1.1	40
61	Long-Term Effects of Nucleus Accumbens Deep Brain Stimulation in Treatment-Resistant Depression: Evidence for Sustained Efficacy. Neuropsychopharmacology, 2012, 37, 1975-1985.	5.4	310
62	Diffusion Tensor Imaging and Neuromodulation. International Review of Neurobiology, 2012, 107, 207-234.	2.0	59
63	Panksepp's SEEKING System Concepts and Their Implications for the Treatment of Depression with Deep-Brain Stimulation. Neuropsychoanalysis, 2012, 14, 43-45.	0.7	1
64	The hidden third: improving outcome in treatment-resistant depression. Journal of Psychopharmacology, 2012, 26, 587-602.	4.0	56
65	Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice, 2012, 16, 77-84.	2.4	327
66	Brain stimulation therapies for neuropsychiatric disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 106, 681-695.	1.8	17
67	Fear Processing and Social Networking in the Absence of a Functional Amygdala. Biological Psychiatry, 2012, 72, 70-77.	1.3	123
68	A neuromodulation experience registry for deep brain stimulation studies in psychiatric research: Rationale and recommendations for implementation. Brain Stimulation, 2012, 5, 653-655.	1.6	18
69	Overnight deprivation from smoking disrupts amygdala responses to fear. Human Brain Mapping, 2012, 33, 1407-1416.	3.6	5
70	Aripiprazole in patients with bipolar mania and beyond: an update of practical guidance. Current Medical Research and Opinion, 2011, 27, 2285-2299.	1.9	11
71	Pegylated human interferon alpha 2a does not induce depression-associated changes in mice. Psychiatry Research, 2011, 185, 243-247.	3.3	9
72	Modulating Affect, Cognition, and Behavior – Prospects of Deep Brain Stimulation for Treatment-Resistant Psychiatric Disorders. Frontiers in Integrative Neuroscience, 2011, 5, 29.	2.1	21

#	Article	IF	CITATIONS
73	Cross-species affective functions of the medial forebrain bundleâ€"Implications for the treatment of affective pain and depression in humans. Neuroscience and Biobehavioral Reviews, 2011, 35, 1971-1981.	6.1	227
74	Antidepressant effects, of magnetic seizure therapy and electroconvulsive therapy, in treatment-resistant depression. Journal of Psychiatric Research, 2011, 45, 569-576.	3.1	144
75	Chronic vagus nerve stimulation for treatment-resistant depression increases regional cerebral blood flow in the dorsolateral prefrontal cortex. Psychiatry Research - Neuroimaging, 2011, 191, 153-159.	1.8	76
76	Electrodes in the brainâ€"Ethical criteria for research and treatment with deep brain stimulation for neuropsychiatric disorders. Brain Stimulation, 2011, 4, 7-16.	1.6	55
77	Depression comorbidity in spinocerebellar ataxia. Movement Disorders, 2011, 26, 870-876.	3.9	69
78	Neuropsychological safety of nucleus accumbens deep brain stimulation for major depression: Effects of 12-month stimulation. World Journal of Biological Psychiatry, 2011, 12, 516-527.	2.6	95
79	FDA Exemptions: The Authors Reply. Health Affairs, 2011, 30, 1212-1212.	5.2	4
80	Humanitarian Device Exemptions: The Authors Reply. Health Affairs, 2011, 30, 1213-1213.	5.2	2
81	Ethical guidance for the management of conflicts of interest for researchers, engineers and clinicians engaged in the development of therapeutic deep brain stimulation. Journal of Neural Engineering, 2011, 8, 033001.	3.5	30
82	Citalopram plus low-dose pipamperone <i>versus</i> citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response. Psychological Medicine, 2011, 41, 2089-2097.	4.5	15
83	Misuse Of The FDA's Humanitarian Device Exemption In Deep Brain Stimulation For Obsessive-Compulsive Disorder. Health Affairs, 2011, 30, 302-311.	5.2	100
84	Carotid atherosclerosis in depression and anxiety: Associations for age of depression onset. World Journal of Biological Psychiatry, 2011, 12, 549-558.	2.6	32
85	Two-Year Outcome of Vagus Nerve Stimulation in Treatment-Resistant Depression. Journal of Clinical Psychopharmacology, 2010, 30, 273-281.	1.4	137
86	The Clinical Future of Repetitive Transcranial Magnetic Stimulation and Depression: Separating Hope From Hype. CNS Spectrums, 2010, 15, 554-557.	1.2	0
87	Separating Hope from Hype: <i>Some Ethical Implications of the Development of Deep Brain Stimulation in Psychiatric Research and Treatment</i> CNS Spectrums, 2010, 15, 285-287.	1.2	22
88	Deep Brain Stimulation and the Neuroethics of Responsible Publishing. JAMA - Journal of the American Medical Association, 2010, 303, 775.	7.4	106
89	Registering Findings From Deep Brain Stimulation—Reply. JAMA - Journal of the American Medical Association, 2010, 303, 2139.	7.4	0
90	Electrodes in the brainâ€"Ethical criteria for research and treatment with deep brain stimulation for neuropsychiatric disorders. Brain Stimulation, 2010, , .	1.6	2

#	Article	IF	Citations
91	Nucleus Accumbens Deep Brain Stimulation Decreases Ratings of Depression and Anxiety in Treatment-Resistant Depression. Biological Psychiatry, 2010, 67, 110-116.	1.3	729
92	The N-Methyl-D-Aspartate Receptor Co-agonist D-Cycloserine Facilitates Declarative Learning and Hippocampal Activity in Humans. Biological Psychiatry, 2010, 67, 1205-1211.	1.3	90
93	Intracranial EEG Correlates of Expectancy and Memory Formation in the Human Hippocampus and Nucleus Accumbens. Neuron, 2010, 65, 541-549.	8.1	166
94	WFSBP Guidelines on Brain Stimulation Treatments in Psychiatry. World Journal of Biological Psychiatry, 2010, 11, 2-18.	2.6	93
95	Neuromodulation – ECT, rTMS, DBS. International Library of Ethics, Law, and the New Medicine, 2010, , 299-320.	0.5	8
96	FDA Considers Classification of ECT. CNS Spectrums, 2009, 14, 668-670.	1.2	1
97	Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opinion on Pharmacotherapy, 2009, 10, 927-936.	1.8	38
98	Reduced 5-HT2Areceptor signaling following selective bilateral amygdala damage. Social Cognitive and Affective Neuroscience, 2009, 4, 79-84.	3.0	24
99	Neuroelectric Signatures of Reward Learning and Decision-Making in the Human Nucleus Accumbens. Neuropsychopharmacology, 2009, 34, 1649-1658.	5.4	64
100	Scientific and Ethical Issues Related to Deep Brain Stimulation for Disorders of Mood, Behavior, and Thought. Archives of General Psychiatry, 2009, 66, 931.	12.3	159
101	Good Vibrations: Cross-frequency Coupling in the Human Nucleus Accumbens during Reward Processing. Journal of Cognitive Neuroscience, 2009, 21, 875-889.	2.3	177
102	Nuclei Accumbens Phase Synchrony Predicts Decision-Making Reversals Following Negative Feedback. Journal of Neuroscience, 2009, 29, 7591-7598.	3.6	82
103	Noradrenergic enhancement of amygdala responses to fear. Social Cognitive and Affective Neuroscience, 2009, 4, 119-126.	3.0	139
104	Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). Journal of Psychiatric Research, 2009, 43, 568-575.	3.1	24
105	Controversy: Repetitive transcranial magnetic stimulation or transcranial direct current stimulation shows efficacy in treating psychiatric diseases (depression, mania, schizophrenia,) Tj ETQq1 1 0.784314 rgBT /Ove	erlock 10°	Tf7 5 0 177 To
106	Clozapine: Acquittal of the usual suspect. World Journal of Biological Psychiatry, 2009, 10, 981-984.	2.6	3
107	Magnetic Seizure Therapy of Treatment-Resistant Depression in a Patient With Bipolar Disorder. Journal of ECT, 2009, 25, 137-140.	0.6	35
108	Deep brain stimulation for psychiatric disorders â€" state of the art. Advances and Technical Standards in Neurosurgery, 2009, 34, 37-57.	0.5	34

#	Article	IF	Citations
109	Stimulating personality: Ethical criteria for deep brain stimulation in psychiatric patients and for enhancement purposes. Biotechnology Journal, 2008, 3, 1511-1520.	3.5	155
110	Modeling a Negative Response Bias in the Human Amygdala by Noradrenergic–Glucocorticoid Interactions. Journal of Neuroscience, 2008, 28, 12868-12876.	3.6	103
111	Cerebral blood flow effects of acute intravenous heroin administration. European Neuropsychopharmacology, 2008, 18, 278-285.	0.7	19
112	Deep Brain Stimulation to Reward Circuitry Alleviates Anhedonia in Refractory Major Depression. Neuropsychopharmacology, 2008, 33, 368-377.	5.4	893
113	Vagus nerve stimulation for depression: efficacy and safety in a European study. Psychological Medicine, 2008, 38, 651-661.	4.5	179
114	Pattern ofÂregional cerebral blood-flow changes induced byÂacute heroin administration – aÂperfusion MRI study. Journal of Neuroradiology, 2007, 34, 322-329.	1.1	13
115	Mood improvement after deep brain stimulation of the internal globus pallidus for tardive dyskinesia in a patient suffering from major depression. Journal of Psychiatric Research, 2007, 41, 801-803.	3.1	97
116	Repetitive transcranial magnetic stimulation (rTMS) in depression. Poiesis & Praxis, 2006, 4, 111-127.	0.3	2
117	Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex affects divided attention immediately after cessation of stimulation. Journal of Psychiatric Research, 2006, 40, 315-321.	3.1	56
118	Decreased frontal white-matter volume in chronic substance abuse. International Journal of Neuropsychopharmacology, 2006, 9, 147.	2.1	94
119	Deep-Brain Stimulation for Parkinson's Disease. New England Journal of Medicine, 2006, 355, 2256-2256.	27.0	5
120	Incident Mania During Therapy With Vagus Nerve Stimulation. Journal of ECT, 2005, 21, 197.	0.6	14
121	Brain Stimulation in Depression. , 2005, , 403-425.		2
122	ECT and rTMS for depression. British Journal of Psychiatry, 2005, 187, 386-386.	2.8	1
123	Cognitive Improvement in Schizophrenic Patients does not Require a Serotonergic Mechanism: Randomized Controlled Trial of Olanzapine vs Amisulpride. Neuropsychopharmacology, 2005, 30, 381-390.	5.4	75
124	Deep brain stimulation for treatment of refractory depression. Lancet, The, 2005, 366, 1420-1422.	13.7	106
125	Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression. British Journal of Psychiatry, 2005, 186, 410-416.	2.8	97
126	Diminished GABAA Receptor-Binding Capacity and a DNA Base Substitution in a Patient with Treatment-Resistant Depression and Anxiety. Neuropsychopharmacology, 2004, 29, 347-350.	5.4	14

#	Article	IF	Citations
127	Repetitive transcranial magnetic stimulation: a putative add-on treatment for major depression in elderly patients. Psychiatry Research, 2004, 126, 123-133.	3.3	158
128	Novel physical treatments for major depression: vagus nerve stimulation, transcranial magnetic stimulation and magnetic seizure therapy. Current Opinion in Psychiatry, 2004, 17, 15-20.	6.3	13
129	Learning From the History of Neuroscience: Dogma and Patient Interests. Journal of ECT, 2004, 20, 137-138.	0.6	1
130	Induced Seizures as Psychiatric Therapy. Journal of ECT, 2004, 20, 133-136.	0.6	16
131	Transcranial magnetic stimulation. Neurosurgery Clinics of North America, 2003, 14, 283-301.	1.7	51
132	Beyond the Treatment of Epilepsy: New Applications of Vagus Nerve Stimulation in Psychiatry. CNS Spectrums, 2003, 8, 515-521.	1.2	36
133	Repetitive transcranial magnetic stimulation for the treatment of depression. British Journal of Psychiatry, 2003, 182, 480-491.	2.8	279
134	Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Affective Disorders. Neuropsychopharmacology, 2003, 28, 201-205.	5.4	58
135	Magnetic Seizure Therapy Improves Mood in Refractory Major Depression. Neuropsychopharmacology, 2003, 28, 2045-2048.	5.4	111
136	Safety and Feasibility of Magnetic Seizure Therapy (MST) in Major Depression: Randomized Within-Subject Comparison with Electroconvulsive Therapy. Neuropsychopharmacology, 2003, 28, 1852-1865.	5.4	236
137	Progress in Therapeutic Brain Stimulation in Neuropsychiatry. CNS Spectrums, 2003, 8, 488-488.	1.2	2
138	International Society for Transcranial Stimulation Consensus Statement: Managing the Risks of Repetitive Transcranial Stimulation. CNS Spectrums, 2003, 8, 489-489.	1.2	53
139	Mechanisms and State of the Art of Vagus Nerve Stimulation. Journal of ECT, 2002, 18, 189-192.	0.6	21
140	Did Ezekiel Have Temporal Lobe Epilepsy?. Archives of General Psychiatry, 2002, 59, 561.	12.3	62
141	Hemispheric asymmetry in visuospatial attention assessed with transcranial magnetic stimulation. Experimental Brain Research, 2002, 143, 426-430.	1.5	72
142	High frequency repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral cortex: EEG topography during waking and subsequent sleep. Psychiatry Research - Neuroimaging, 2001, 107, 1-9.	1.8	28
143	Double-pulse transcranial magnetic stimulation over the frontal eye field facilitates triggering of memory-guided saccades. European Journal of Neuroscience, 2001, 14, 571-575.	2.6	31
144	Cerebral blood flow in obsessive–compulsive patients with major depression: effect of treatment with sertraline or desipramine on treatment responders and non-responders. Psychiatry Research - Neuroimaging, 2001, 108, 89-100.	1.8	40

#	Article	IF	CITATIONS
145	Magnetic Seizure Therapy of Major Depression. Archives of General Psychiatry, 2001, 58, 303.	12.3	178
146	Mood effects of repetitive transcranial magnetic stimulation of left prefrontal cortex in healthy volunteers. Psychiatry Research, 2000, 94, 251-256.	3.3	83
147	SPECT brain blood flow changes with continuous ligand infusion during previously-learned WCST performance. Psychiatry Research - Neuroimaging, 1998, 82, 47-52.	1.8	16
148	Repetitive transcranial magnetic stimulation activates specific regions in rat brain. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 15635-15640.	7.1	179
149	Onset and recovery from panic disorder in the Baltimore Epidemiologic Catchment Area follow-up. British Journal of Psychiatry, 1998, 173, 501-507.	2.8	66
150	Site of Opioid Action in the Human Brain: Mu and Kappa Agonists' Subjective and Cerebral Blood Flow Effects. American Journal of Psychiatry, 1998, 155, 470-473.	7.2	137
151	PET study of competition between intravenous cocaine and [11C]raclopride at dopamine receptors in human subjects. American Journal of Psychiatry, 1997, 154, 1209-1213.	7.2	118
152	Mood Effects of Prefrontal Repetitive High-Frequency TMS in Healthy Volunteers. CNS Spectrums, 1997, 2, 53-68.	1.2	42
153	Neuroimaging in Affective Disorders: Accomplishments and Shortfalls. Child and Adolescent Psychiatric Clinics of North America, 1997, 6, 413-430.	1.9	2
154	Exploratory factor analysis of MRI brain structure measures in schizophrenia. Schizophrenia Research, 1996, 19, 93-101.	2.0	44
155	Suicide reporting in the Swiss print media. European Journal of Public Health, 1995, 5, 199-203.	0.3	26
156	Structural differences in the cerebral cortex of healthy female and male subjects: a magnetic resonance imaging study. Psychiatry Research - Neuroimaging, 1995, 61, 129-135.	1.8	194
157	Pitfalls of SPECT Studies of Acute Ethanol-Induced Changes in Cerebral Blood Flow. American Journal of Psychiatry, 1995, 152, 1695-1695.	7.2	2
158	The involvement of benzodiazepine receptor ligands in hepatic encephalopathy. Hepatology, 1994, 20, 541-543.	7.3	11
159	Detection of benzodiazepine-like activity in hepatic encephalopathy requires an initial lipophilic extraction procedure!. Hepatology, 1994, 20, 544-546.	7.3	2
160	Decreased regional cortical gray matter volume in schizophrenia. American Journal of Psychiatry, 1994, 151, 842-848.	7.2	365
161	Increased benzodiazepine-like activity is neither necessary nor sufficient to explain acute hepatic encephalopathy in the thioacetamide-treated rat. Hepatology, 1993, 18, 1459-1464.	7.3	19
162	Paradoxical effects of mild hypoxia and moderate altitude on human visual perception. Clinical Science, 1992, 83, 633-636.	4.3	17

#	Article	IF	CITATIONS
163	WFSBP Guidelines on Brain Stimulation Treatments in Psychiatry. World Journal of Biological Psychiatry, 0, , 1-17.	2.6	6